Device Trial Radar · NCT01729247
Study to Evaluate the Impact of FeNO Assessments on Asthma Management Decisions in Subject 7 to 60 Years of Age
Last checked: Nov 19, 2026Latest source record: Mar 3, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
50
Actual
Start
Oct 2012
Primary completion
Nov 2012
Study completion Nov 2012
Sponsor
- Lead sponsor
- Aerocrine ABNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 20, 2012
Design
- Study type
- Observational
- Who can join
- All sexes, from 7 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective: To evaluate the impact of FeNO assessments on asthma treatment decisions. Secondary objectives: Evaluate the ability of physicians to correctly assess airway inflammation using standard clinical assessment tools (i.e., prior to FeNO measurement). Estimate the cost consequences of changes in asthma management following FeNO determinations Number of participants: Approximately 40 to 50 subjects will participate in the study during an (approximately) 8-12 week study enrollment period. Reference product: NIOX MINO® Instrument (09-1100) Performance assessments: Fractional Exhaled Nitric Oxide (FeNO) Measurements will be performed according to the "Perform FeNO Measurement" guidelines on page 7 of the NIOX MINO® User Manual (February, 2011). Response to Study Physician Questions before (Questions 1, 2, and 3) and after (Question 4) FeNO has been measured and seen by the Physician/Health Care Practitioner. Safety assessments: The Investigator is responsible for the detection, reporting, and documentation of events meeting the definition of an Adverse Event (AE) and/or Serious Injuries as provided in this clinical investigation plan (CIP) from the time that informed consent has been provided and during the study period Criteria for evaluation: This is an observational, pilot study and there are currently no plans for a formal statistical analysis. Information gained from this study may be used to design subsequent studies in subjects with asthma. Data collected will be summarized in a clinical study report but will not be subject to formal hypothesis testing
Conditions
- Asthma
Interventions
NIOX MINO® Instrument (09-1100)Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- FeNO Values by ACT ScoreTime frame: Study Visit (single visit study). Approximately 1 hour.
- FeNO Categorical Levels by ICS UseTime frame: Study visit (single visit study). Approximately1 hour.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
North Carolina Clinical Research
Raleigh, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.